Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191451 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL555256 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL1693182 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL3343104 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL3344958 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL765453 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL16125648 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL1045289 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL21032211 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL23463705 | 0.98 | BTK (0.49) | BTKCA1CA2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836032-A | Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine | 泰州葛林美克医药科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| EP-4722196-A1 | CRYSTAL OF VIRAL PROTEASE INHIBITOR AND USE | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-116836032-B | Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine | 泰州葛林美克医药科技有限公司 | 2025-07-18 | — | — | CN | disclosed |
| CN-116836032-B | Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine | 泰州葛林美克医药科技有限公司 | 2025-07-18 | — | — | CN | disclosed |
| WO-2025045761-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025045758-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4512427-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| US-6794389-B2 | Quinazoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BTK 27/4885CA1 4622/4885CA2 4617/4885 |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BTK 3419/4885CA1 896/4885CA2 1018/4885 |
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | BTK 673/4885CA1 2568/4885CA2 843/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BTK 3419/4885CA1 896/4885CA2 1018/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | BTK 2285/4885CA1 1160/4885CA2 1699/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | BTK 1123/4885CA1 3944/4885CA2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.